Glomerular diseases: Registries and clinical trials

Clinical Journal of the American Society of Nephrology

Volumn 11, Issue 12, 2016, Pages 2234-2243

  Moxey Mims, Marva M ^a   Flessner, Michael F ^a   Holzman, Lawrence ^b   Kaskel, Frederick ^c   Sedor, John R ^d   Smoyer, William E ^e   Thompson, Aliza M ^f   Yao, Lynne ^f  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Chronic; Clinical trial; Cooperative Behavior; Electronic Health Records; Foundations; Glomerular disease; Government; Humans; Kidney; Kidney Failure; Kidney Glomerulus; Nephrology; Patient Advocacy; Phenotype; Prevalence; Registries; Research; Science; Specialization

Indexed keywords

ABATACEPT; ANIFROLUMAB; AVACOPAN; BELIMUMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FRESOLIMUMAB; LAQUINIMOD; MYCOPHENOLATE MOFETIL; OBINUTUZUMAB; RITUXIMAB; SPARSENTAN; VOCLOSPORIN; BIOLOGICAL MARKER;

ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL RESEARCH; DISEASE COURSE; END STAGE RENAL DISEASE; FOCAL GLOMERULOSCLEROSIS; FUNDING; GLOMERULOPATHY; HEALTH INSURANCE; HISTOPATHOLOGY; HUMAN; INVESTMENT; MEDICAL INFORMATION; PATIENT-REPORTED OUTCOME; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; RANDOMIZED CONTROLLED TRIAL (TOPIC); BIOASSAY; ECONOMICS; KIDNEY DISEASE; LIPOID NEPHROSIS; MEMBRANOUS GLOMERULONEPHRITIS; METHODOLOGY; NATIONAL HEALTH ORGANIZATION; NEPHROLOGY; PEDIATRICS; PUBLIC-PRIVATE PARTNERSHIP; REGISTER; STANDARDS; STATISTICS AND NUMERICAL DATA; UNITED STATES;

BIOMARKERS; ENDPOINT DETERMINATION; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY DISEASES; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES (U.S.); NEPHROLOGY; NEPHROSIS, LIPOID; PEDIATRICS; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; RESEARCH DESIGN; UNITED STATES;

EID: 85021716380     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00540116     Document Type: Article

References (33)

1. Strippoli GFM, Craig JC, Schena FP: The number, quality, and coverage of randomized controlled trials in nephrology. J AmSoc Nephrol 15: 411-419, 2004
2. de Zeeuw D, deGraeff PA: Clinical trial in nephrology at hard end point? J Am Soc Nephrol 15: 506-508, 2004
3. Inrig JK, Califf RM, Tasneem A, Vegunta RK, Molina C, Stanifer JW, Chiswell K, Patel UD: The landscape of clinical trials in nephrology: A systematic review of Clinicaltrials.gov. Am J Kidney Dis 63: 771-780, 2014
4. Samuels JA, Molony DA: Randomized controlled trials in nephrology: State of the evidence and critiquing the evidence. Adv Chronic Kidney Dis 19: 40-46, 2012
5. Himmelfarb J: Chronic kidney disease and the public health:Gaps in evidence from interventional trials. JAMA 297: 2630-2633, 2007
6. Ferris M, Norwood V, Radeva M, Gassman JJ, Al-Uzri A, Askenazi D, Matoo T, Pinsk M, Sharma A, Smoyer W, Stults J, Vyas S, Weiss R, Gipson D, Kaskel F, Friedman A, Moxey-Mims M, Trachtman H: Patient recruitment into a multicenter randomized clinical trial for kidney disease: Report of the focal segmental glomerulosclerosis clinical trial (FSGS CT). Clin Transl Sci 6: 13-20, 2013
7. Levey AS, Cattran D, Friedman A, Miller WG, Sedor J, Tuttle K, Kasiske B, Hostetter T: Proteinuria as a surrogate outcome in CKD: Report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 54: 205-226, 2009
8. Ronco P: Moderator’s view: Biomarkers in glomerular diseases-translated into patient care or lost in translation? Nephrol Dial Transplant 30: 899-902, 2015
9. Thompson A, Cattran DC, Blank M, Nachman PH: Complete and partial remission as surrogate end points in membranous nephropathy. J Am Soc Nephrol 26: 2930-2937, 2015
10. Beck LH Jr., Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ: M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361: 11-21, 2009
11. Lalwani P, de Souza GKBB, de Lima DSN, Passos LFS, Boechat AL, Lima ES: Serum thiols as a biomarker of disease activity in lupus nephritis. PLoS One 10: e0119947, 2015
12. Birmingham DJ, Bitter JE, Ndukwe EG, Dials S, Gullo TR, Conroy S, Nagaraja HN, Rovin BH, Hebert LA: Relationship of circulating anti-C3b and anti-C1q IgGto lupus nephritis and its flare. Clin J Am Soc Nephrol 11: 47-53, 2016
13. O’Reilly VP, Wong L, Kennedy C, Elliot LA, O’Meachair S, Coughlan AM, O’Brien EC, Ryan MM, Sandoval D, Connolly E, Dekkema GJ, Lau J, Abdulahad WH, Sanders JF, Heeringa P, Buckley C, O’Brien C, Finn S, Cohen CD, Lindemeyer MT, Hickey FB, O’Hara PV, Feighery C, Moran SM, Mellotte G, Clarkson MR, Dorman AJ, Murray PT, Little MA: Urinary soluble CD163 in active renal vasculitis [published online ahead of printMarch 3, 2016]. J Am Soc Nephrol doi: 10.1681/ASN.2015050511
14. Gipson DS, Trachtman H, Kaskel FJ, Radeva MK, Gassman J, Greene TH, Moxey-Mims MM, Hogg RJ, Watkins SL, Fine RN, Middleton JP, Vehaskari VM, Hogan SL, Vento S, Flynn PA, Powell LM, McMahan JL, Siegel N, Friedman AL: Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life. Kidney Int 79: 678-685, 2011
15. Gipson DS, Trachtman H, Kaskel FJ, Greene TH, Radeva MK, Gassman JJ, Moxey-Mims MM, Hogg RJ, Watkins SL, Fine RN, Hogan SL, Middleton JP, Vehaskari VM, Flynn PA, Powell LM, Vento SM, McMahan JL, Siegel N, D’Agati VD, Friedman AL: Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 80: 868-878, 2011
16. Osafo C, Raji YR, Burke D, Tayo BO, Tiffin N, Moxey-Mims MM, Rasooly RS, Kimmel PL, Ojo A, Adu D, Parekh RS; H3 Africa Kidney Disease Research Network Investigators as members of The H3 Africa Consortium: Human heredity and health (H3) in Africa Kidney Disease Research Network: A focus on methods in sub-Saharan Africa. Clin J AmSocNephrol 10: 2279-2287, 2015
17. Coffey CS, Levin B, Clark C, Timmerman C, Wittes J, Gilbert P, Harris S: Overview, hurdles, and future work in adaptive designs: Perspectives from a National Institutes of Health-funded workshop. Clin Trials 9: 671-680, 2012
18. US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research: FDA Draft Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics, 2010. Available at: http://www.fda.gov/downloads/ Drugs/…/Guidances/ucm201790.pdf. Accessed July 28, 2016
19. Food and Drug Administration: 110-85 (Food and Drug Administration Amendments Act), and Permanently Reauthorized in 2012 by Pub. L. 112-114 (Food and Drug Administration Safety and Innovation Act), 2012
20. Food and Drug Administration: Best Pharmaceuticals for Children Act, Pub. L. 107-109 (2002). Reauthorized in 2007 by Pub. L. 110-85 (Food andDrug Administration Amendments Act), and Permanently Reauthorized in 2012 by Pub. L. 112-114 (Food and Drug Administration Safety and Innovation Act), 2012
21. Food and Drug Administration: Pediatric Research Equity Act. Pub L. 108-155 (2003). Reauthorized in 2007 by Pub. L. 110-85 (Food and Drug Administration Amendments Act), and Permanently Reauthorized in 2012 by Pub. L. 112-114 (Food and Drug Administration Safety and Innovation Act), 2012
22. US Department of Health and Human Services, Food and Drug Administration, Specific Requirements on Content and Format of Labeling for Human Prescription Drugs; Revision of “pediatric use” Subsection In the Labeling, Final Rule. Federal Register Volume 59, Number 238 (Tuesday, December 13, 1994)
23. Food andDrug Administration: Specific requirements on content and format of labeling for human prescription drugs: Revision of “pediatric use” subsection in the labeling: Final rule. Fed Regist 59: 238, 1994
24. Dunne J, Rodriguez WJ, Murphy MD, Beasley BN, Burckart GJ, Filie JD, Lewis LL, Sachs HC, Sheridan PH, Starke P, Yao LP: Extrapolation of adult data and other data in pediatric drugdevelopment programs. Pediatrics 128: e1242-e1249, 2011
25. Coorevits P, Sundgren M, Klein GO, Bahr A, Claerhout B, Daniel C, Dugas M, Dupont D, Schmidt A, Singleton P, De Moor G, Kalra D: Electronic health records: New opportunities for clinical research. J Intern Med 274: 547-560, 2013
26. Sullivan GM: Getting off the “gold standard”: Randomized controlled trials and education research. J Grad Med Educ 3: 285-289, 2011
27. Ware JH, Hamel MB: Pragmatic trials-guides to better patient care? N Engl J Med 364: 1685-1687, 2011
28. Hudson KL, Collins FS: Bringing the common rule into the 21st century. N Engl J Med 373: 2293-2296, 2015
29. Cola PA, Reider C, Strasser JE: Ohio CTSAs implement a reliant IRB model for investigator-initiated multicenter clinical trials. Clin Transl Sci 6: 176-178, 2013
30. Reith C, Landray M, Devereaux PJ, Bosch J, Granger CB, Baigent C, Califf RM, Collins R, Yusuf S: Randomized clinical trials-removing unnecessary obstacles. N Engl J Med 369: 1061-1065, 2013
31. Morris HK, Canetta PA, Appel GB: Impact of the ALMS and MAINTAIN trials on the management of lupus nephritis. Nephrol Dial Transplant 28: 1371-1376, 2013
32. Hogan J, Avasare R, Radhakrishnan J: Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis. Clin J Am Soc Nephrol 9: 1657-1667, 2014
33. Perkovic V, Neal B: Trials in kidney disease-time to EVOLVE. N Engl J Med 367: 2541-2542, 2012